The Biologics News and Reports Portal

Show Cart

All Products

Results 61 - 80 of 102

Jun 2018 Competitor Analysis: CTLA-4, LAG-3, TIM-3, TIGIT & Other Immune Checkpoint Inhibitors 2018

500.00 €

Jun 2018 Competitor Analysis: PD-1 and PD-L1 Immune Checkpoint Inhibitors 2018

600.00 €

Jun 2018 Competitor Analysis: MAGE-A-Targeted Immunotherapy

150.00 €

Jun 2018 Competitor Analysis: NY-ESO-1-Targeted Immunotherapy

400.00 €

Jun 2018 Competitor Analysis: hTERT-Targeted Immunotherapy

150.00 €

Jun 2018 Competitor Analysis: WT1-Targeted Immunotherapy

300.00 €

Jun 2018 Competitor Analysis: PRAME-Targeted Immunotherapy

150.00 €

May 2018 Competitor Analysis: Survivin-Targeted Immunotherapy

200.00 €

May 2018 TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals

2,150.00 €

Mar 2018 Blockbuster Biologics 2017: Sales of Recombinant Therapeutic Antibodies & Proteins

80.00 €

Jan 2018 Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends

2,300.00 €

Jun 2017 mRNA Vaccines & Therapeutics 2017: an industry analysis of technologies, pipelines, stakeholders and deals

2,250.00 €

Mar 2017 Blockbuster Biologics 2016: Sales of Recombinant Therapeutic Antibodies & Proteins

70.00 €

Jan 2017 The Oncolytic Virus Landscape 2017: an analysis of pipeline, stakeholders, deals, industry trends & opportunities

2,150.00 €

Nov 2016 CD22: a suitable antigen for targeted payload delivery by immunotherapeutics

700.00 €

Shopping cart

Cart empty

Latest report

B7-H3-Targeted Immunotherapy Candidates Pipeline Review

Featured Products

Claudin 18.2-Targeted Immunotherapy: a landscape analysis of stakeholders, drug modalities, pipeline and business opportunities from an industry perspective

CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing

RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry perspective

Latest Target Pipeline

DLL3-Targeted Immunotherapy Candidates Pipeline Review

Shopping cart

Cart empty

Latest report

B7-H3-Targeted Immunotherapy Candidates Pipeline Review

Featured Products

Claudin 18.2-Targeted Immunotherapy: a landscape analysis of stakeholders, drug modalities, pipeline and business opportunities from an industry perspective

CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing

All Products

Jul 2018 OX40 Immune Checkpoint Activators – Target Pipeline List 07/2018

Jul 2018 CD27 Immune Checkpoint Activators – Target Pipeline List 07/2018

Jul 2018 ICOS Immune Checkpoint Activators – Target Pipeline List 07/2018

Jul 2018 PD-1 Immune Checkpoint Inhibitors – Target Pipeline List 07/2018

Jul 2018 PD-L1 Immune Checkpoint Inhibitors – Target Pipeline List 07/2018

Jun 2018 Competitor Analysis: CTLA-4, LAG-3, TIM-3, TIGIT & Other Immune Checkpoint Inhibitors 2018

Jun 2018 Competitor Analysis: PD-1 and PD-L1 Immune Checkpoint Inhibitors 2018

Jun 2018 Competitor Analysis: MAGE-A-Targeted Immunotherapy

Jun 2018 Competitor Analysis: NY-ESO-1-Targeted Immunotherapy

Jun 2018 Competitor Analysis: hTERT-Targeted Immunotherapy

Jun 2018 Competitor Analysis: WT1-Targeted Immunotherapy

Jun 2018 Competitor Analysis: PRAME-Targeted Immunotherapy

May 2018 Competitor Analysis: Survivin-Targeted Immunotherapy

May 2018 TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals

Mar 2018 Blockbuster Biologics 2017: Sales of Recombinant Therapeutic Antibodies & Proteins

Jan 2018 Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends

Jun 2017 mRNA Vaccines & Therapeutics 2017: an industry analysis of technologies, pipelines, stakeholders and deals

Mar 2017 Blockbuster Biologics 2016: Sales of Recombinant Therapeutic Antibodies & Proteins

Jan 2017 The Oncolytic Virus Landscape 2017: an analysis of pipeline, stakeholders, deals, industry trends & opportunities

Nov 2016 CD22: a suitable antigen for targeted payload delivery by immunotherapeutics

Shopping cart

Latest report

Featured Products

Latest Target Pipeline

Shopping cart

Latest report

Featured Products

Latest Target Pipeline

La Merie Biologics

FREE Weekly News Bulletin

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing